Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer-Reference-Cited by-同舟云学术

Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Published:2018-10-21 Issue:2 Volume:125 Page:278-289
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chu Jacqueline N.¹,Choi Jin²^ORCID,Ostvar Sassan²^ORCID,Torchia James A.³,Reynolds Kerry Lynn⁴,Tramontano Angela²,Gainor Justin F.⁴,Chung Daniel C.⁵,Clark Jeffrey W.⁴,Hur Chin¹²⁵⁶

Affiliation:

1. Department of Medicine; Massachusetts General Hospital; Boston Massachusetts

2. Institute for Technology Assessment; Massachusetts General Hospital; Boston Massachusetts

3. Dana-Farber Cancer Institute; Boston Massachusetts

4. Massachusetts General Hospital Cancer Center; Boston Massachusetts

5. Division of Gastroenterology; Massachusetts General Hospital; Boston Massachusetts

6. Columbia University Irving Medical Center; New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31795/fullpdf

Reference48 articles.

1. Randomized trial of TAS-102 for refractory metastatic colorectal cancer;Mayer;N Engl J Med,2015

2. Metastatic colorectal cancer: current state and future directions;Fakih;J Clin Oncol,2015

3. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study;Overman;Lancet Oncol,2017

4. PD-1 blockade in tumors with mismatch-repair deficiency;Le;N Engl J Med,2015

5. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade;Le;Science,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation on the cost–effectiveness of Cetuximab in treatment of colorectal cancer: a systematic review;Colorectal Cancer;2024-08-27

2. Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study;Value in Health;2024-07

3. Immunotherapy in Colorectal Cancer — Finding the Achilles’ Heel;NEJM Evidence;2024-05-28

4. Targeted delivery of T-cell agonists for enhancing immunotherapy;Journal of Drug Delivery Science and Technology;2023-11

5. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan;Japanese Journal of Clinical Oncology;2023-05-31